A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma

Trial Profile

A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 18 Sep 2015 According to Ziopharm media release, results presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
    • 25 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 11 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top